12 feb: Indre værdi af SmallCap Danmark A/S er opgjort til 20,6 kr. pr. a..
12-02-2019 02:07:44

Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) Split Dosing Regimen

Media Release

Copenhagen, Denmark, February 12, 2019

  • DARZALEX split dosing regimen approved by U.S. FDA

  • Provides healthcare professionals with option to split first DARZALEX infusion over two consecutive days

  • Approval supported by data from EQUULEUS (MMY1001) clinical trial

Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the U.S. Food and Drug Administration (U.S. FDA) has approved a split dosing regimen for DARZALEX® (daratumumab).  The approval will be included in an update to the Prescribing Information in order to provide healthcare professionals the option to split the first infusion of DARZALEX over two consecutive days. The supplemental Biologics License Application (sBLA) was submitted by Genmab’s licensing partner, Janssen Biotech, Inc., in July, 2018. The split dosing option was previously approved in Europe by the European Commission in December 2018. In August 2012, Genmab granted Janssen an exclusive worldwide license to develop, manufacture and commercialize daratumumab.

“We are pleased that, with this change, patients in the U.S. receiving their first infusion of DARZALEX may now have this more flexible dosing option,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab

This approval was supported by data from the Phase Ib EQUULEUS (MMY1001) clinical trial, which demonstrated DARZALEX pharmacokinetics (PK) concentrations were comparable regardless of whether the first dose was administered as a split infusion or as a single first infusion in patients with multiple myeloma. The safety profile of DARZALEX was comparable when administered initially as either a split or a single dose.

About the EQUULEUS (MMY1001) Study

The Phase Ib EQUULEUS open-label study includes up to 240 patients with the goal of evaluating the safety, tolerability and dose of daratumumab when administered in combination with various backbone treatment regimens for different settings of multiple myeloma.




DARZALEX® (daratumumab) injection for intravenous infusion is indicated in the United States in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI); and as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a PI and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.1 DARZALEX is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration (U.S. FDA) approval to treat multiple myeloma. DARZALEX is indicated in Europe in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; and as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. The option to split the first infusion of DARZALEX over two consecutive days has been approved in both Europe and the U.S. In Japan, DARZALEX is approved in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adults with relapsed or refractory multiple myeloma.  DARZALEX is the first human CD38 monoclonal antibody to reach the market in the United Stated, Europe and Japan.  For more information, visit www.DARZALEX.com.

Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells.  Daratumumab triggers a person’s own immune system to attack the cancer cells, resulting in rapid tumor cell death through multiple immune-mediated mechanisms of action and through immunomodulatory effects, in addition to direct tumor cell death, via apoptosis (programmed cell death).1,2,3,4,5

Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab. A comprehensive clinical development program for daratumumab is ongoing, including multiple Phase III studies in smoldering, relapsed and frontline multiple myeloma settings and in amyloidosis.  Additional studies are ongoing or planned to assess the potential of daratumumab in other malignant and pre-malignant diseases, such as NKT-cell lymphoma, B and T-ALL.  Daratumumab has received two Breakthrough Therapy Designations from the U.S. FDA, for multiple myeloma, as both a monotherapy and in combination with other therapies.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications and other blood cancers.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies and the HexElect™ platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products.  Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.


Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication

T: +45 33 44 77 20; E: rcg@genmab.com

This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody™; HexElect™; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

1 DARZALEX Prescribing information, February 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761036s016lbl.pdf Last accessed February 2019

2 De Weers, M et al. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. The Journal of Immunology. 2011; 186: 1840-1848.

3 Overdijk, MB, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015; 7: 311-21.

4Krejcik, MD et al. Daratumumab Depletes CD38+ Immune-regulatory Cells, Promotes T-cell Expansion, and Skews T-cell Repertoire in Multiple Myeloma. Blood. 2016; 128: 384-94.

5Jansen, JH  et al. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking. Blood. 2012; 120(21): abstract 2974.



Media Release no. 02

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V




Relateret indhold
21 maj - 
Aktier/åbning: Demant og Genmab til tops i grønt marked
13 maj - 
Aktier/middag: Ambu bankes ned i rødt marked
10 maj - 
De mest shortede aktier i april – Pandora kravler op af..
Relateret debat
10:45 - 
Hvorfor bruger du ikke Nordnet og dermed realtid
10:44 - 
10:43 - 
Der skal ikke meget til: www.netfonds.no/quotes/ppaper...

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
16 maj
Som gentogen har skrevet på PI, så er det ligeledes ret interessant at JNJ har listet tre DuoBodies ..
16 maj
Uddrag fra præsentationen på JNJs analytiker dag: “The Oncology unit reported global growth of 14.5%..
20 maj
Men for at svare på dit spørgsmål vedr. kort og langsigtet vil vi se den brage op igennem taget kort..
20 maj
Vi kan forvente os milepælsbetalinger og synes det er værd at bemærke denne:Eksempelvis estimerede a..
21 maj
Det lugter af en godkendelse lige om hjørnet....
20 maj
Nu er "brage op igennem taget" og "voldsom stigning" jo relativ. Hvad er voldsom stigning - 10 % ? D..
20 maj
Godt skrevet spekulanten89. Jeg er 100% enig. Har også et million beløb i Genmab.. Langsigtet.
Den skal lige presses op over 1200, det er et psykologisk stærkt tal så mon ikke vi kan se 1210 idag..
$$$ :)
20 maj
Jeg er ikke i tvivl om godkendelse, dertil er Darzalex trackrecord og testresultater for gode. Derim..

Telegiganters fusion møder modstand: Aktierne står til kursfald

22-05-2019 14:58:35
Relaterede nyheder
Aktierne i de amerikanske teleselskaber Sprint og T-Mobile ser ud til at skulle falde onsdag, efter at der er kommet forlydender om, at det amerikanske justitsministerium vil stille sig i vejen for selskabernes fusion.Ifølge Reuters er justitsministeriet ikke tilfreds med den plan for fusionen, som Sprint og T-Mobile selv har præsenteret, og det skal have fået ministeriet til at begynde at arbejde..

Zealand Pharma indleder nyt forsøg med partner

22-05-2019 14:19:28
Zealand Pharma og den amerikanske partner Beta Bionics har startet et forsøg, hvor det danske selskabs middel Dasiglucagon kombineres med partnerens pumpesystem iLet.Det fortæller Zealand Pharma i en selskabsmeddelelse.Intentionen med forsøget er at finde ud af, om selskaberne kan udvikle en form for kunstigt bugspytkirtelsystem, hvor det danske selskabs bidrag er Dasiglucagon til behandling af ty..

Simcorp slår regnskabs-forventninger - aktien til tops i C25

22-05-2019 08:54:19
Softwareselskabet Simcorp har i første kvartal af 2019 haft en omsætning, der endte højere sammenlignet med samme kvartal året før. For indtjeningen var der ligeledes tale om fremgang i kvartalet, der bød på indgåede aftaler med to nye kunder.Det viser regnskabet for første kvartal, som er offentliggjort onsdag morgen.Omsætningen sluttede i første kvartal på 99,7 mio. euro mod 89,9 mio. euro i sam..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
Bavarian/CEO: Som investor bør man være begejstret for RSV-kandidat
Aktier/tendens: Simcorp og Bavarian i fokus efter regnskaber
Bavarian/Sydbank: Kommende nyheder kan sende aktien yderligere op
Bavarian Nordic Q1: Fastholder forventningerne til "overgangsår"
Zealand Pharma indleder nyt forsøg med partner

Relaterede aktiekurser

Genmab A/S 1,203.00 0,4% Stigning i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
22. maj 2019 20:03:24
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190514.2 - EUROWEB1 - 2019-05-22 20:03:24 - 2019-05-22 20:03:24 - 1 - Website: OKAY